September 1, 2015Journal of Clinical Oncology483 citationsOpen Access

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

KKKaren Kelly NANasser K. Altorki WEWilfried Eberhardt

Key Points

Key points are not available for this paper at this time.

Abstract

Adjuvant erlotinib did not prolong DFS in patients with EGFR-expressing NSCLC or in the EGFRm-positive subgroup. Further evaluation of erlotinib is warranted in the EGFRm-positive subgroup.

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Kelly et al. (2015) studied this question.

synapsesocial.com/papers/69dcc30ed4d0de07d11339bd https://doi.org/10.1200/jco.2015.61.8918

Ask AI

Helpful

Bookmark

View Full Paper

September 1, 2015Journal of Clinical Oncology483 citationsOpen Access

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

KKKaren Kelly NANasser K. Altorki WEWilfried Eberhardt

Key Points

Key points are not available for this paper at this time.

Abstract

Adjuvant erlotinib did not prolong DFS in patients with EGFR-expressing NSCLC or in the EGFRm-positive subgroup. Further evaluation of erlotinib is warranted in the EGFRm-positive subgroup.

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Kelly et al. (2015) studied this question.

synapsesocial.com/papers/69dcc30ed4d0de07d11339bd https://doi.org/10.1200/jco.2015.61.8918

Ask AI

Helpful

Bookmark

View Full Paper